Evaluation of abnormal iron distribution in specific regions in the brains of patients with Parkinson's disease using quantitative susceptibility mapping and R2* mapping

Cheng,Qingqing; Huang,Jiaxi; Liang,Jianye; Ma,Mengjie; Zhao,Qian; Lei,Xueping; Shi,Changzheng; Luo,Liangping

doi:10.3892/etm.2020.8645

Evaluation of abnormal iron distribution in specific regions in the brains of patients with Parkinson's disease using quantitative susceptibility mapping and R2* mapping

Authors:
- Qingqing Cheng
- Jiaxi Huang
- Jianye Liang
- Mengjie Ma
- Qian Zhao
- Xueping Lei
- Changzheng Shi
- Liangping Luo
View Affiliations

Affiliations: Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, P.R. China, School of Public Health, Guangzhou Medical University, Guangzhou, Guangdong 511436, P.R. China, Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences and Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510799, P.R. China
Published online on: April 3, 2020 https://doi.org/10.3892/etm.2020.8645
Pages: 3778-3786
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The primary aim of the present study was to evaluate abnormal iron distribution in specific regions of the brains in patients with Parkinson's disease (PD) using quantitative susceptibility mapping (QSM) and R2* mapping, and to compare the diagnostic performances of QSM and R2* mapping in differentiating patients with PD with that in normal controls. A total of 25 patients with idiopathic PD and 28 sex‑and age‑matched normal controls were included in the present study and their brains investigated using a 3T scanner. Magnetic resonance imaging techniques, namely, QSM and R2* mapping, were applied to generate susceptibility and R2* values. The differences in susceptibility and R2* values in deep grey matter nuclei between patients with PD and the normal controls were compared using independent samples t‑tests. The abilities of QSM and R2* mapping to classify patients with PD and normal controls were analyzed using receiver operating characteristic curves. Correlation analyses between imaging parameters (e.g. susceptibility and R2* values) and clinical feature (disease severity assessed using the Hoehn and Yahr score) were performed. The intra‑class correlation coefficient (ICC) for susceptibility (ICC=0.977; P<0.001) and R2* (ICC=0.945; P<0.001) values between two neuro‑radiologists were >0.81, showing excellent inter‑rater agreement. The susceptibility values were significantly increased in the substantia nigra (SN) and red nucleus, but were decreased in the putamen of patients with PD compared with that in the corresponding brain regions of normal controls. However, increased R2* values were observed only in the SN in patients with PD. QSM showed higher sensitivity and specificity compared with R2* mapping to separate the patients with PD from the normal controls. There were no significant correlations between the susceptibility/R2* values and clinical features in all targeted regions of the brains in patients with PD. In conclusion, both QSM and R2* mapping are feasible to calculate the iron levels in human brains, and QSM provides a more sensitive and accurate method to assess regional abnormal iron distribution in patients with PD.

View Figures

View References

1	Marino BLB, Souza LR, Sousa KPA, Ferreira JV, Padilha EC, Silva CHTP, Taft CA and Hage-Melim LIS: Parkinson's disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment. Mini Rev Med Chem: Nov 3, 2019 (Epub ahead of print). doi: 10.2174/1389557519666191104110908.
2	de Lau LM and Breteler MM: Epidemiology of Parkinson's disease. Lancet Neurol. 5:525–535. 2006.PubMed/NCBI View Article : Google Scholar
3	Fasano M, Bergamasco B and Lopiano L: Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem. 96:909–916. 2006.PubMed/NCBI View Article : Google Scholar
4	Griffiths PD and Crossman AR: Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia. 4:61–65. 1993.PubMed/NCBI View Article : Google Scholar
5	Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P and Marsden CD: Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 114:1953–1975. 1991.PubMed/NCBI View Article : Google Scholar
6	Dusek P, Jankovic J and Le W: Iron dysregulation in movement disorders. Neurobiol Dis. 46:1–18. 2012.PubMed/NCBI View Article : Google Scholar
7	Rhodes SL, Buchanan DD, Ahmed I, Taylor KD, Loriot MA, Sinsheimer JS, Bronstein JM, Elbaz A, Mellick GD, Rotter JI and Ritz B: Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrin. Neurobiol Dis. 62:172–178. 2014.PubMed/NCBI View Article : Google Scholar
8	Sian-Hulsmann J, Mandel S, Youdim MB and Riederer P: The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem. 118:939–957. 2011.PubMed/NCBI View Article : Google Scholar
9	Andersen JK: Oxidative stress in neurodegeneration: Cause or consequence? Nat Med. 10 (Suppl):S18–S25. 2004.PubMed/NCBI View Article : Google Scholar
10	Tysnes OB and Storstein A: Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 124:901–905. 2017.PubMed/NCBI View Article : Google Scholar
11	Hardy PA, Gash D, Yokel R, Andersen A, Ai Y and Zhang Z: Correlation of R2 with total iron concentration in the brains of rhesus monkeys. J Magn Reson Imaging. 21:118–127. 2005.PubMed/NCBI View Article : Google Scholar
12	Aquino D, Bizzi A, Grisoli M, Garavaglia B, Bruzzone MG, Nardocci N, Savoiardo M and Chiapparini L: Age-related iron deposition in the basal ganglia: Quantitative analysis in healthy subjects. Radiology. 252:165–172. 2009.PubMed/NCBI View Article : Google Scholar
13	Hallgren B and Sourander P: The effect of age on the non-haemin iron in the human brain. J Neurochem. 3:41–51. 1958.PubMed/NCBI View Article : Google Scholar
14	Ropele S, Wattjes MP, Langkammer C, Kilsdonk ID, Graaf WL, Frederiksen JL, Fuglø D, Yiannakas M, Wheeler-Kingshott CA, Enzinger C, et al: Multicenter R2^* mapping in the healthy brain. Magn Reson Med. 71:1103–1107. 2014.PubMed/NCBI View Article : Google Scholar
15	Du G, Lewis MM, Styner M, Shaffer ML, Sen S, Yang QX and Huang X: Combined R2^* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord. 26:1627–1632. 2011.PubMed/NCBI View Article : Google Scholar
16	Martin WR, Wieler M and Gee M: Midbrain iron content in early Parkinson disease: A potential biomarker of disease status. Neurology. 70:1411–1417. 2008.PubMed/NCBI View Article : Google Scholar
17	Kennan RP, Zhong J and Gore JC: Intravascular susceptibility contrast mechanisms in tissues. Magn Reson Med. 31:9–21. 1994.PubMed/NCBI View Article : Google Scholar
18	Fernandez-Seara MA and Wehrli FW: Postprocessing technique to correct for background gradients in image-based R^*(2) measurements. Magn Reson Med. 44:358–366. 2000.PubMed/NCBI View Article : Google Scholar
19	Liu C, Li W, Tong KA, Yeom KW and Kuzminski S: Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain. J Magn Reson Imaging. 42:23–41. 2015.PubMed/NCBI View Article : Google Scholar
20	Li W, Wu B and Liu C: Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition. NeuroImage. 55:1645–1656. 2011.PubMed/NCBI View Article : Google Scholar
21	Liu T, Spincemaille P, de Rochefort L, Kressler B and Wang Y: Calculation of susceptibility through multiple orientation sampling (COSMOS): A method for conditioning the inverse problem from measured magnetic field map to susceptibility source image in MRI. Magn Reson Med. 61:196–204. 2009.PubMed/NCBI View Article : Google Scholar
22	Langkammer C, Schweser F, Krebs N, Deistung A, Goessler W, Scheurer E, Sommer K, Reishofer G, Yen K, Fazekas F, et al: Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. NeuroImage. 62:1593–1599. 2012.PubMed/NCBI View Article : Google Scholar
23	Liu T, Eskreis-Winkler S, Schweitzer AD, Chen W, Kaplitt MG, Tsiouris AJ and Wang Y: Improved subthalamic nucleus depiction with quantitative susceptibility mapping. Radiology. 269:216–223. 2013.PubMed/NCBI View Article : Google Scholar
24	Langkammer C, Pirpamer L, Seiler S, Deistung A, Schweser F, Franthal S, Homayoon N, Katschnig-Winter P, Koegl-Wallner M, Pendl T, et al: Quantitative Susceptibility Mapping in Parkinson's Disease. PLoS One. 11(e0162460)2016.PubMed/NCBI View Article : Google Scholar
25	Murakami Y, Kakeda S, Watanabe K, Ueda I, Ogasawara A, Moriya J, Ide S, Futatsuya K, Sato T, Okada K, et al: Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease. AJNR Am J Neuroradiol. 36:1102–1108. 2015.PubMed/NCBI View Article : Google Scholar
26	He N, Ling H, Ding B, Huang J, Zhang Y, Zhang Z, Liu C, Chen K and Yan F: Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping. Hum Brain Mapp. 36:4407–4420. 2015.PubMed/NCBI View Article : Google Scholar
27	Hughes AJ, Daniel SE, Kilford L and Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 55:181–184. 1992.PubMed/NCBI View Article : Google Scholar
28	Hoehn MM and Yahr MD: Parkinsonism: Onset, progression, and mortality. 1967. Neurology. 57 (10 Suppl 3):S11–S26. 2001.PubMed/NCBI
29	Wu B, Li W, Guidon A and Liu C: Whole brain susceptibility mapping using compressed sensing. Magn Reson Med. 67:137–147. 2012.PubMed/NCBI View Article : Google Scholar
30	Schweser F, Deistung A, Lehr BW and Reichenbach JR: Quantitative imaging of intrinsic magnetic tissue properties using MRI signal phase: An approach to in vivo brain iron metabolism? NeuroImage. 54:2789–2807. 2011.PubMed/NCBI View Article : Google Scholar
31	Li W, Wang N, Yu F, Han H, Cao W, Romero R, Tantiwongkosi B, Duong TQ and Liu C: A method for estimating and removing streaking artifacts in quantitative susceptibility mapping. NeuroImage. 108:111–122. 2015.PubMed/NCBI View Article : Google Scholar
32	Li W, Langkammer C, Chou YH, Petrovic K, Schmidt R, Song AW, Madden DJ, Ropele S and Liu C: Association between increased magnetic susceptibility of deep gray matter nuclei and decreased motor function in healthy adults. NeuroImage. 105:45–52. 2015.PubMed/NCBI View Article : Google Scholar
33	Li W, Wu B, Batrachenko A, Bancroft-Wu V, Morey RA, Shashi V, Langkammer C, De Bellis MD, Ropele S, Song AW and Liu C: Differential developmental trajectories of magnetic susceptibility in human brain gray and white matter over the lifespan. Hum Brain Mapp. 35:2698–2713. 2014.PubMed/NCBI View Article : Google Scholar
34	Lewis MM, Du G, Kidacki M, Patel N, Shaffer ML, Mailman RB and Huang X: Higher iron in the red nucleus marks Parkinson's dyskinesia. Neurobiol Aging. 34:1497–1503. 2013.PubMed/NCBI View Article : Google Scholar
35	Zywicke HA, van Gelderen P, Connor JR, Burdo JR, Garrick MD, Dolan KG, Frank JA and Bulte JW: Microscopic R2^* mapping of reduced brain iron in the Belgrade rat. Ann Neurol. 52:102–105. 2002.PubMed/NCBI View Article : Google Scholar
36	Liu C, Wei H, Gong NJ, Cronin M, Dibb R and Decker K: Quantitative susceptibility mapping: Contrast mechanisms and clinical applications. Tomography. 1:3–17. 2015.PubMed/NCBI View Article : Google Scholar
37	Griffiths PD, Dobson BR, Jones GR and Clarke DT: Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain. 122:667–673. 1999.PubMed/NCBI View Article : Google Scholar
38	Meineke J, Rauscher A, Marques JP, Bilgic B and Langkammer C: Quantitative Susceptibility Mapping in Parkinson's Disease. Magnetic Resonance Med. 11(e0162460)2016.PubMed/NCBI View Article : Google Scholar
39	Double KL, Gerlach M, Youdim MB and Riederer P: Impaired iron homeostasis in Parkinson's disease. J Neural Transm Suppl. S37–S58. 2000.PubMed/NCBI View Article : Google Scholar
40	Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB and Riederer P: Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox Res. 5:35–44. 2003.PubMed/NCBI View Article : Google Scholar
41	Zecca L, Youdim MB, Riederer P, Connor JR and Crichton RR: Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 5:863–873. 2004.PubMed/NCBI View Article : Google Scholar
42	Gerlach M, Double KL, Youdim MB and Riederer P: Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl. S133–S142. 2006.PubMed/NCBI View Article : Google Scholar
43	Drayer B, Burger P, Darwin R, Riederer S, Herfkens R and Johnson GA: MRI of brain iron. AJR Am J Roentgenol. 147:103–110. 1986.PubMed/NCBI View Article : Google Scholar
44	Habas C and Cabanis EA: Cortical projection to the human red nucleus: Complementary results with probabilistic tractography at 3 T. Neuroradiology. 49:777–784. 2007.PubMed/NCBI View Article : Google Scholar
45	Lapresle J and Hamida MB: The dentato-olivary pathway. Somatotopic relationship between the dentate nucleus and the contralateral inferior olive. Arch Neurol. 22:135–143. 1970.PubMed/NCBI View Article : Google Scholar
46	Bird TD and Shaw CM: Progressive myoclonus and epilepsy with dentatorubral degeneration: A clinicopathological study of the Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry. 41:140–149. 1978.PubMed/NCBI View Article : Google Scholar
47	Graham JM, Paley MN, Grunewald RA, Hoggard N and Griffiths PD: Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 123 Pt. 12:2423–2431. 2000.PubMed/NCBI View Article : Google Scholar
48	Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD and Coates TD: MRI R2 and R2^* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 106:1460–1465. 2005.PubMed/NCBI View Article : Google Scholar
49	Homayoon N, Pirpamer L, Franthal S, Katschnig-Winter P, Kögl M, Seiler S, Wenzel K, Hofer E, Deutschmann H, Fazekas F, et al: Nigral iron deposition in common tremor disorders. Mov Disord. 34:129–132. 2019.PubMed/NCBI View Article : Google Scholar
50	Barbosa JH, Santos AC, Tumas V, Liu M, Zheng W, Haacke EM and Salmon CE: Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2. Magn Reson Imaging. 33:559–565. 2015.PubMed/NCBI View Article : Google Scholar
51	Lotfipour AK, Wharton S, Schwarz ST, Gontu V, Schäfer A, Peters AM, Bowtell RW, Auer DP, Gowland PA and Bajaj NP: High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging. 35:48–55. 2012.PubMed/NCBI View Article : Google Scholar
52	Eapen M, Zald DH, Gatenby JC, Ding Z and Gore JC: Using high-resolution MR imaging at 7T to evaluate the anatomy of the midbrain dopaminergic system. AJNR Am J Neuroradiol. 32:688–694. 2011.PubMed/NCBI View Article : Google Scholar
53	Schafer A, Forstmann BU, Neumann J, Wharton S, Mietke A, Bowtell R and Turner R: Direct visualization of the subthalamic nucleus and its iron distribution using high-resolution susceptibility mapping. Hum Brain Mapp. 33:2831–2842. 2012.PubMed/NCBI View Article : Google Scholar